Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
$3.65
+2.5%
$6.58
$3.06
$135.54
$2.92M-0.1692,867 shs47,313 shs
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$0.00
$0.00
$0.00
$710K-0.21127,366 shsN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$3.77
-0.5%
$3.47
$2.85
$29.44
$2.78M-0.07113,296 shs5,878 shs
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
$2.43
-6.2%
$2.97
$2.36
$60.80
$2.50M0.19128,027 shs38,886 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
+2.53%+7.35%-40.80%-57.65%-93.46%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00%0.00%0.00%-50.00%0.00%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
-1.41%-2.58%-2.08%+8.96%-73.32%
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
-6.18%-20.33%-15.03%-42.97%-92.52%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
2.9867 of 5 stars
3.55.00.00.01.14.20.0
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
0.5867 of 5 stars
0.04.00.00.00.60.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
3.00
Buy$180.004,831.51% Upside
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00
N/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
0.00
N/AN/AN/A
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NPHC, REVB, QLGN, and ALZN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/17/2025
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$288.00 ➝ $180.00
(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
N/AN/AN/AN/A($3.52) per shareN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$4.98M0.56N/AN/A($20.31) per share-0.19
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
N/AN/AN/AN/A$402.10 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
-$9.95MN/A0.00N/AN/AN/AN/A-289.14%7/29/2025 (Estimated)
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
-$13.42MN/A0.00N/AN/AN/A-424.18%5/26/2025 (Estimated)
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
-$120K-$102.61N/AN/AN/AN/A-193.51%-84.00%8/8/2025 (Estimated)

Latest NPHC, REVB, QLGN, and ALZN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
-$6.88-$2.11+$4.77-$2.11N/AN/A
3/10/2025Q3 2025
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
-$2.61-$1.71+$0.90-$0.19N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
N/AN/AN/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/A
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
N/A
3.80
3.80
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/A
0.52
0.52
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
N/A
1.64
1.64

Institutional Ownership

CompanyInstitutional Ownership
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
49.61%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
3.18%
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
12.80%

Insider Ownership

CompanyInsider Ownership
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
30.21%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
61.50%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
1.80%
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
4801,0004.86 millionNo Data
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
47.10 billion2.73 billionNot Optionable
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
50736,000723,000Not Optionable
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
10964,000268,000Not Optionable

Recent News About These Companies

REVB Start 1B Trial and Announces Split
Revelation Biosciences Inc trading halted, news pending
Revelation Biosciences announces 1-for-16 reverse stock split
Revelation Biosciences starts Phase 1b clinical study of Gemini in CKD

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alzamend Neuro stock logo

Alzamend Neuro NASDAQ:ALZN

$3.65 +0.09 (+2.53%)
Closing price 05/23/2025 03:56 PM Eastern
Extended Trading
$3.64 -0.02 (-0.41%)
As of 05/23/2025 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Nutra Pharma stock logo

Nutra Pharma OTCMKTS:NPHC

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

Qualigen Therapeutics stock logo

Qualigen Therapeutics NASDAQ:QLGN

$3.77 -0.02 (-0.53%)
Closing price 05/23/2025 03:58 PM Eastern
Extended Trading
$3.76 -0.01 (-0.16%)
As of 05/23/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Revelation Biosciences stock logo

Revelation Biosciences NASDAQ:REVB

$2.43 -0.16 (-6.18%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$2.46 +0.03 (+1.44%)
As of 05/23/2025 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.